Iron Chelator Research: Past, Present, and Future
The DOI matches its Crossref record.
Abstract
The occurrence of in vivo iron toxicity in the human body can be categorized into iron overload and non-iron overload conditions. Iron overload conditions are common in beta-thalassemia and hereditary hemochromatosis patients, and anthracycline mediated cardiotoxicity is an example of a non-iron overload condition in cancer patients, in which the toxicity is iron-dependent. While hundreds of iron chelators have been evaluated in animal studies, only a few have been studied in humans. Examples of iron chelator drugs are desferrioxamine (DFO), deferiprone (L1), and dexrazoxane (ICRF 187). The compound ICL670 has completed phase II clinical trials and a phase III trial is planned in 2003. Triapine is currently in phase II clinical trial as an anticancer agent. CP502, GT56-252, NaHBED, and MPB0201 are examples of new chelators in preclinical/clinical development. In the past decade, many new viable utilities for iron chelators have been reported. This includes the use of iron chelators as antiviral, photoprotective, antiproliferative, and antifibrotic agents. This review will focus on the status of drug development for the treatment of iron overload in patients with beta-thalassemia and the potential use of iron chelators in the prevention and treatment of other diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
Kalinowski, D. S., & Richardson, D. R. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.4.2 · Cited by 721
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Oxidative Stress and Iron Homeostasis: Mechanistic and Health Aspects
Galaris, D., & Pantopoulos, K. (2008) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360701713104 · Cited by 352
Ribonucleotide Reductase Inhibitors and Future Drug Design
Shao, J., Zhou, B., Chu, B., & Yen, Y. (2006) · Current Cancer Drug Targets · doi:10.2174/156800906777723949 · Cited by 284
Mitochondrial hTERT exacerbates free‐radical‐mediated mtDNA damage
Santos, J. H., Meyer, J. N., Skorvaga, M., Annab, L. A., & Van Houten, B. (2004) · Aging Cell · doi:10.1111/j.1474-9728.2004.00124.x · Cited by 264
Potential involvement of iron in the pathogenesis of peritoneal endometriosis
Defrere, S., Lousse, J. C., Gonzalez-Ramos, R., Colette, S., Donnez, J., & Van Langendonckt, A. (2008) · Molecular Human Reproduction · doi:10.1093/molehr/gan033 · Cited by 204
Alves, F., Lane, D., Nguyen, T. P. M., Bush, A. I., & Ayton, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02088-5 · Cited by 180
Minding metals: Tailoring multifunctional chelating agents for neurodegenerative disease
Perez, L. R., & Franz, K. J. (2010) · Dalton Trans. · doi:10.1039/b919237a · Cited by 156
Peritoneal endometriosis is an inflammatory disease
Donnez, J. (2012) · Frontiers in Bioscience · doi:10.2741/e358 · Cited by 127
Recent developments on 3-hydroxy-4-pyridinones with respect to their clinical applications
Santos, M. A. (2008) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2008.01.033 · Cited by 54
Meyer, D. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206777442164 · Cited by 34
“Because of structural differences between DFO (a hexadentate ligand, [26, 16]) and L1 (a bidentate ligand, [26, 16]), the iron inactivating capacity of the latter chelator is concentration dependant [24].”
BackgroundInfluentialLousse, J.-C., Defrère, S., Ramos, R. G., Van Langendonckt, A., Colette, S., & Donnez, J. (2009) · Journal of Endometriosis · doi:10.1177/228402650900100104 · Cited by 10
“Treatment with desferrioxamine (DFO), a common iron chelator, has proved beneficial and is currently used for pathologies characterized by iron overload, such as β-thalassemia and hereditary hemochromatosis (33).”
Background
Metadata
- Authors
- Tam, T., Leung-Toung, R., Li, W., Wang, Y., Karimian, K., & Spino, M.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2003-06-01
- Volume
- 10
- Issue
- 12
- Pages
- 983-995
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2063479802
- Cited by
- 116
- References
- 0
- FWCI
- 5.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.